La Universal Research Center Inc

1. Eli Lilly and Company $898,078 16 payments
2. Sanofi US Services Inc. $855,878 32 payments
3. Gilead Sciences, Inc. $379,796 13 payments
4. Dr.Reddy's Laboratories,Inc. $273,324 37 payments
5. Sun Pharmaceutical Industries Inc. $90,479 20 payments
6. E.R. Squibb & Sons, L.L.C. $71,576 2 payments
7. Dermira, Inc. $33,136 1 payment
8. Pfizer Inc. $26,270 9 payments
9. Bausch Health US, LLC $20,932 2 payments
10. Galderma Laboratories, L.P. $19,252 6 payments

1. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $381,765 14 payments
2. Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $370,068 12 payments
3. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $251,469 3 payments
4. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $233,734 4 payments
5. Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis $191,698 30 payments
6. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $163,296 2 payments
7. Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting $117,354 1 payment
8. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $112,360 3 payments
9. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment $93,745 5 payments
10. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $89,967 1 payment

1. Professional salary support $64,844 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.